Núria Farré*, José Belda-Sanchis, Mauro Guarino, Laura Tilea, Jady Vivian Rojas Cordero, Elisabeth Martínez-Téllez
Farré et al. J Clin Transl Res 2021; 7(1):11
Published online: February 17, 2021
Abstract
Background: Early stage small cell lung cancer (T1-2N0M0SCLC) represents 7% of all SCLC. The standard treatment in patients with intrathoracic SCLC disease is the use of concurrent chemoradiotherapy (CRT). Nowadays, the recommended management of this highly selected group is surgical resection due to favorable survival outcomes. For medically inoperable patients or those who refuse surgery, there is an increasing interest in evaluating the role of Stereotactic Body Radiotherapy (SBRT) for T1-2N0SCLC, transferring the favorable experience obtained on inoperable NSCLC (Non-Small-cell Lung Cancer). In the era of multimodality treatment, adjuvant systemic therapy plays an important role even in the management of early SCLC, increasing the disease-free survival (DFS) and Overall Survival (OS). The benefit of Prophylactic Cranial Irradiation (PCI), that currently has a category I recommendation for localized stage SLCL, remains controversial in this selected subgroup of patients due to the lower risk of brain metastasis.
Aim: This review summarizes the most relevant data on the local management of T1-2N0M0SCLC (surgery and radiotherapy), and evaluates the relevance of adjuvant treatment.
Relevance for patients: Provides a critical evaluation of best current clinical management options for T1-2N0M0 SCLC.
DOI: http://dx.doi.org/10.18053/jctres.07.202101.011
Author affiliation
1. Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau.
Universitat Autònoma de Barcelona, Barcelona, Spain
2. Department of Thoracic Surgery, Hospital de la Santa Creu i Sant Pau.
Universitat Autònoma de Barcelona, Barcelona, Spain
*Corresponding author
Núria Farré
Department of Radiation Oncology. Hospital de la Santa Creu i Sant Pau. Barcelona. Universitat Autònoma de Barcelona, Barcelona, Spain. Sant Quintí, 89. 08041 Barcelona
Tel: 0034 935537756
Email: nfarre@santpau.cat
Handling editor:
Michal Heger
Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China
Download
Full text PDF
Review process file (197.4 KB)
